Status:
COMPLETED
Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19)
Lead Sponsor:
Guangzhou Institute of Respiratory Disease
Conditions:
Covid-19
Hydrogen/Oxygen Mixed Gas
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This was a randomized, multi-center, open-label clinical trial. Eligible patients were recruited from seven hospitals in China. On the basis of standard-of-care, patients in treatment group inhaled H2...
Detailed Description
This was a randomized, multi-center, open-label clinical trial. Eligible patients were recruited from seven hospitals in China. On the basis of standard-of-care, patients in treatment group inhaled H2...
Eligibility Criteria
Inclusion
- Patients with lab-confirmed Covid-19 aged 18 to 75 years.
- Had dyspnea both on hospital admission and at enrollment.
- The patients volunteered to participate in this study and signed the informed consent
Exclusion
- Have other systemic diseases other than COVID-19 -- a disease that, according to the investigator's judgment, might increase the risk of developing adverse outcomes or affect the outcome measures after participation in the study.
- Women who are pregnant or breastfeeding or plan to be pregnant during the study.
- Subjects with one of the following respiratory diseases:
- Subjects in critical or unstable conditions. Critical (meeting any of the following symptoms): 1. Respiratory failure occurs and mechanical ventilation is needed; 2. Shock occurs; 3. Other organ failure, ICU monitoring and treatment is needed.
- Having immunosuppressive diseases (HIV), severe neurological disease affecting upper respiratory tract control, or other risk factors that the investigator believes can cause a significant risk of pneumonia in subjects.
- Subjects with mental disorder and cognitive impairment.
- Subjects who do not follow the study steps.
- Patients with mental retardation, poor motivation, drug abuse (including drugs and alcohol) or other disease history restricting the effectiveness of informed consent in this study.
- Use of antioxidants, including large doses of vitamin C and vitamin E.
- Subjects who are not suitable for participation in this study in the judgment of investigator.
Key Trial Info
Start Date :
January 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 23 2020
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04378712
Start Date
January 21 2020
End Date
March 23 2020
Last Update
May 15 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China